CARISMA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.08 USD | -2.70% |
|
-18.80% | -63.14% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 118.2 | 44.87 | - | - |
| Enterprise Value (EV) 1 | 118.2 | 44.87 | 44.87 | 44.87 |
| P/E ratio | -1.13 x | -0.86 x | -0.87 x | -0.79 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 7.93 x | 2.89 x | 6.23 x | - |
| EV / Revenue | 7.93 x | 2.89 x | 6.23 x | - |
| EV / EBITDA | - | - | - | - |
| EV / FCF | -1.44 x | -1.25 x | -0.92 x | -0.85 x |
| FCF Yield | -69.6% | -80.2% | -109% | -118% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 40,357 | 41,543 | - | - |
| Reference price 2 | 2.930 | 1.080 | 1.080 | 1.080 |
| Announcement Date | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 14.92 | 15.52 | 7.197 | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -88.73 | -66.13 | -78.55 | -91.61 |
| Operating Margin | - | -594.75% | -426.09% | -1,091.42% | - |
| Earnings before Tax (EBT) 1 | - | -86.88 | -60.43 | -73.01 | -84.3 |
| Net income 1 | -61.23 | -86.88 | -60.43 | -73.01 | -84.31 |
| Net margin | - | -582.34% | -389.38% | -1,014.4% | - |
| EPS 2 | -54.65 | -2.590 | -1.262 | -1.245 | -1.370 |
| Free Cash Flow 1 | - | -82.31 | -36 | -49 | -53 |
| FCF margin | - | -551.71% | -231.95% | -680.84% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 4/4/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.243 | 3.56 | 3.827 | 4.289 | 3.397 | 3.924 | 4.299 | 3.899 | 2.399 | 2.399 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -22.97 | -20.96 | -22.34 | -22.45 | -19.51 | -15.05 | -15.25 | -16.32 | -13.95 | -14.5 |
| Operating Margin | -708.36% | -588.9% | -583.85% | -523.43% | -574.33% | -383.58% | -354.67% | -418.54% | -581.49% | -604.42% |
| Earnings before Tax (EBT) 1 | -24.53 | -19.79 | -21.4 | -21.16 | -18.98 | -13.28 | -13.53 | -14.65 | -13.39 | -14.1 |
| Net income 1 | -24.64 | -19.88 | -21.4 | -20.96 | -18.98 | -13.28 | -13.53 | -14.65 | -13.39 | -14.1 |
| Net margin | -759.85% | -558.31% | -559.26% | -488.65% | -558.67% | -338.5% | -314.61% | -375.61% | -558.32% | -587.54% |
| EPS 2 | -1.930 | -0.4900 | -0.5300 | -0.4800 | -0.4600 | -0.2975 | -0.2650 | -0.2700 | -0.3133 | -0.3300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 5/11/23 | 8/10/23 | 11/9/23 | 4/1/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -82.3 | -36 | -49 | -53 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | - | 1 | 2 |
| Capex / Sales | - | - | - | 13.89% | - |
| Announcement Date | 4/4/23 | 4/1/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.08
USD
Average target price
7.6
USD
Spread / Average Target
+603.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -63.14% | 44.87M | |
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.21B | |
| +2.45% | 22.78B | |
| -10.39% | 17.96B | |
| -41.74% | 16.43B | |
| -13.31% | 16.37B | |
| +2.44% | 13.58B | |
| +27.89% | 11.66B |
- Stock Market
- Equities
- CARM Stock
- Financials Carisma Therapeutics, Inc.
